Eli Lilly Acquires 4E Therapeutics Again; Broadcom Chairman Increases Stock Holdings
Miles Bennett
Eli Lilly made its second painkiller acquisition in two months, snapping up oral MNK-inhibitor developer 4E Therapeutics; Broadcom's chairman bought 1,000 shares after the stock fell over $100 from its peak — both moves point to the same thing: cash-rich companies are buying the dip.
Why did Lilly buy another pain-drug company?
4E Therapeutics is developing oral chronic-pain drugs. Its lead compound is an MNK inhibitor — a new class of painkiller that avoids opioids entirely, aiming to relieve pain without addiction.
Phase 1 data showed a clean safety profile, but the deal price was not disclosed. This means → 4E is still very early-stage; Lilly is buying a ticket to the race, not a finished product.
In May 2025, Lilly paid $1 billion for SiteOne Therapeutics. Two deals in under two months. In plain terms = Lilly is placing repeated bets on the same thesis: non-addictive painkillers.
How big is this painkiller market — and what could go wrong?
The non-opioid painkiller market has real scale — Vertex's Journavx is already on the market, and SiteOne's lead asset belongs to the same drug class.
But development risk is high: Lilly pulled a painkiller candidate from its pipeline last year. This means → even a company of Lilly's size does not win every bet here.
For investors, obesity and diabetes still drive the vast majority of Lilly's revenue. These acquisitions look more like GLP-1 cash being redeployed to cast a wide net for the next blockbuster.
Why did Broadcom's chairman buy shares right now?
Board chairman Harry You bought 1,000 shares last Thursday at $373.57 each — less than $1 million in total.
The purchase came after Broadcom's stock fell more than $100 from its June 2 high, driven by conservative AI-business guidance. This means → management sees the selloff as overdone and is signaling with real money that the stock looks cheap.
The amount is small — not enough to change the market's fundamental view — but it reads as a positive vote of confidence.
Has Broadcom's management done this before?
Yes. On April 7, 2025, five days after Trump's "Liberation Day" tariffs, CEO Hock Tan announced a $10 billion share-buyback authorization.
Broadcom's stock doubled afterward. In plain terms = the last time management stepped in during a panic, it turned out to be a perfectly timed buy.
The market is now watching whether the company will accelerate its buyback further. This reflects what investors really care about — not the chairman's small purchase itself, but whether it foreshadows a much larger repurchase push.
Content is for reference only, not financial advice.